

VPA10983/054/001

Marbocyl P 5 mg Tablets

Variation	Summary	Date
Vet - G.I.18	VRA-S - Vet - G.I.18 - - Vet - G.I.18 - One-off alignment of the product information with version 9.0* of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products authorised in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	13/04/26
Vet - F.II.c.4 z)	VRA-R - Vet - F.II.c.4 z) - - Vet - F.II.c.4 z) - Change in synthesis or recovery of a non pharmacopoeial excipient (when described in the dossier) or a novel excipient - Other changes under this code level, e.g. variations outlined in section 6 and 7 of this guidance	26/01/26
Vet - B28 a)	VNRA - Vet - B28 a) - a) Tightening of specification limits - B28 a) Changes to the quality part of the dossier: Change in the specification parameters or limits of an excipient — tightening of specification limits	26/02/25
Vet - B12 b)	VNRA - Vet - B12 b) - b) Minor changes to an approved test procedure (starting material, excipient) - B12 b) Changes to the quality part of the dossier: Minor changes — to an approved test procedure — for a starting material, reagent or intermediate used in the manufacturing process of the active substance; — for an excipient	26/02/25
Vet - B28 b)	VNRA - Vet - B28 b) - b) Addition of a new specification parameter to the specification with its corresponding test method - B28 b) Changes to the quality part of the dossier: Change in the specification parameters or limits of an excipient —addition of a new specification parameter to the specification with its corresponding test method	26/02/25
Vet - B3 m)	VNRA - Vet - B3 m) - m) Deletion of a non-significant specification parameter (excipient) - B3 m) Changes to the quality part of the dossier: Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) in the specification parameters or limits of an excipient	26/02/25
Vet - B3 k)	VNRA - Vet - B3 k) - k) Deletion of a non-significant in-process test (finished product manufacture) - B3 k) Changes to the quality part of the dossier: Deletion of a non-significant in-process test (e.g. deletion of an obsolete test) during the manufacture of the finished product	06/07/23
Vet - F.II.b.3 a)	VRA-R - Vet - F.II.b.3 a) - a) Minor change in the manufacturing process - F.II.b.3 a) Quality Changes - Finished Product -Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - Minor change in the manufacturing process	18/05/23

Vet - B3 k)	VNRA - Vet - B3 k) - k) Deletion of a non-significant in-process test (finished product manufacture) - B3 k) Changes to the quality part of the dossier: Deletion of a non-significant in-process test (e.g. deletion of an obsolete test) during the manufacture of the finished product	11/05/23
Vet - B3 k)	VNRA - Vet - B3 k) - k) Deletion of a non-significant in-process test (finished product manufacture) - B3 k) Changes to the quality part of the dossier: Deletion of a non-significant in-process test (e.g. deletion of an obsolete test) during the manufacture of the finished product	09/05/23
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	31/03/23
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	31/03/23
A.7	IA - A.7 - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - A.7 - ADMINISTRATIVE CHANGES - Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)*	06/04/22
B.I.d.1.a.4	IB - B.I.d.1.a.4 - 4. Extension or introduction of a re-test period/storage period supported by real time data - B.I.d.1.a.4 - QUALITY CHANGES - ACTIVE SUBSTANCE - Stability - Change in the re-test period/storage period or storage conditions of the active substance where no Ph. Eur. Certificate of Suitability covering the retest period is part of the approved dossier - Re-test period/storage period -	06/04/22
B.I.b.2.e	IB - B.I.b.2.e - e) Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - B.I.b.2.e - QUALITY CHANGES - ACTIVE SUBSTANCE - Control of active substance - Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate	06/04/22
B.I.b.2.e	IB - B.I.b.2.e - e) Other changes to a test procedure (including replacement or addition) for the active substance or a starting	06/04/22

	material/intermediate - B.I.b.2.e - QUALITY CHANGES - ACTIVE SUBSTANCE - Control of active substance - Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate	
--	---	--